Journals / Ulusal Cerrahi Dergisi / 2010 / Cilt: 26 - Sayı: 2

Promoter polymorphisms of MMP 1 and 2 genes and risk for hepatocellular carcinoma: Case-control analysis in Turkish patients

MMP 1 ve 2 genleri promoter polimorfizmleri ve hepatoselüler karsinom riski: Türk hastalarda olgu-kontrol analizi

Pages
79–84
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: No significant association was determined between Turkish hepatocellular carcinoma prognosis and post-transplantation metastasis and invasion with MMP2 -735 C/T and MMP1 -1607 1G/2G polymorphisms as risk predictors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Matrix metalloproteinases are established as strong prognostic markers for hepatocellular carcinoma which is one of the most progressive and aggressive cancer types worldwide.
📊
Key Findings & Data:Due to asociation with invasion in cancer metastasis, the matrix metalloproteinases MMP-1 and MMP-2 are candidate genes for predisposition to hepatocellular carcinoma.
💡
Conclusion & Impact:Conclusion: No significant association was determined between Turkish hepatocellular carcinoma prognosis and post-transplantation metastasis and invasion with MMP2 -735 C/T and MMP1 -1607 1G/2G polymorphisms as risk predictors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Matrix metalloproteinases are established as strong prognostic markers for hepatocellular carcinoma which is one of the most progressive and aggressive cancer types worldwide. Hepatocellular carcinoma is very common in various populations, but the pathogenetic link between MMPs is limited so far. Due to asociation with invasion in cancer metastasis, the matrix metalloproteinases MMP-1 and MMP-2 are candidate genes for predisposition to hepatocellular carcinoma. Patients and Methods: A total of 73 patients who were diagnosed as having hepatocellular carcinoma and had undergone liver transplantation were enrolled in the study. Following DNA extraction polymerase chain reaction-restriction fragment lenght polymorphism molecular genetic analyses were performed. By case-control and genotype-phenotype correlation analysis, we investigated the risk of association of MMP-1 and MMP-2 promoter polymorphisms in 73 Turkish hepatocellular carcinoma patients compared to healthy controls. Results: Genotypic distributions of the MMP2 -735 C/T and MMP1 -1607 1G/2G polymorphisms were in Hardy-Weinberg equilibrium in patient and control groups (p>0.05). In case-control analyses, the distribution of the genotypes and allele frequencies in the cases did not differ from those in the control group (p>0.05). In genotype-phenotype correlation analysis; for MMP1 -1607 1G/2G polymorphism 2G/2G genotype was associated with portal vein invasion (p<0.02). With regard to the post-transplantation results of the present study the 4-year survival rate in the patients was 77,3% and the recurrencefree survival rate in the post-transplant phase was 96,2%. Conclusion: No significant association was determined between Turkish hepatocellular carcinoma prognosis and post-transplantation metastasis and invasion with MMP2 -735 C/T and MMP1 -1607 1G/2G polymorphisms as risk predictors.

Özet

Amaç: Tüm dünyada en progresif ve agresif kanser türlerinden biri olan hepatoselüler karsinom patogenezinde matriks metalloproteinazlar (MMP) güçlü prognostik indikatörler olarak gösterilmektedir. Ancak, MMPler ile kanıtlanan patogenetik bağlantı son derece sınırlıdır. Kanser metastazında invazyon ile ilişkisi dolayısıyla, matriks metalloproteinaz genleri, hepatoselüler karsinoma yatkınlıkta aday genler olarak düşünülmektedir. Bu çalışmada, MMP2 -735 C/T ve MMP1 -1607 1G/2G genlerinin polimorfizmlerinin hastaların klinikopatolojik değişkenleriyle korelasyonunun araştırılması ve bu klinikopatolojik değişkenlerin hastalık seyrine olan etkisinin değerlendirilmesi amaçlanmıştır. Hastalar ve Yöntem: Çalışmaya, Ege Üniversitesi Organ Nakli Merkezi'nde karaciğer sirozu zemininde gelişmiş hepatoselüler karsinom tanısı ile karaciğer nakli uygulanmış 73 hasta katılmıştır. DNA ekstraksiyonunu takiben polimeraz zincir reaksiyonu-restriksiyon fragment uzunluk polimorfizmi (PCR-RFLP) moleküler genetik analizleri gerçekleştirilmiştir. Olgu-kontrol; genotip-fenotip bağlantı analizleri ile MMP2 -735 C/T ve MMP1 -1607 1G/2G polimorfizmleri hasta ve sağlıklı gruplar arasında risk faktörü olabilirliği açısından incelenmiştir. Bulgular: MMP2 -735 C/T ve MMP1 -1607 1G/2G polimorfizmleri Hardy-Weinberg dengesinde bulunmuştur (p>0,05). Olgu-kontrol analizinde genotip dağılımı ve allel frekansları hasta ve sağlıklı gruplar arasında anlamlı fark göstermemiştir (p>0,05). Genotip - fenotip korelasyon analizinde MMP1 -1607 1G/2G polimorfizmi hasta grubunda 2G/2G genotipi, portal ven invazyonu ile ilişki göstermiştir (p<0,02). Çalışmanın nakil sonrası sonuçlarında, hastalardaki 4 yıllık sağ kalım hızı %77,3 ve nakil sonrası rekürrenssiz sağ kalım hızı da %96,2 olarak bulunmuştur. Sonuç: MMP2 -735 C/T ve MMP1 -1607 1G/2G polimorfizmleri ile Türk hepatoselüler karsinom prognozu ve nakil sonrası metastaz ve invazyonu arasında risk prediktörleri olarak bir bağlantı gözlenmemiştir.

🔖

Cite This Article

KAZIMİ, M., NALBANOĞLU, S. M., KILIÇ, M., BERDELİ, A. (2010). Promoter polymorphisms of MMP 1 and 2 genes and risk for hepatocellular carcinoma: Case-control analysis in Turkish patients. Ulusal Cerrahi Dergisi, Cilt: 26 - Sayı: 2, 79–84. https://ajindex.com/articles/325698

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Kim S., Choi Y., Choung S., Jun J. Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis. Human Reproduction 2005;20: 2904-2908
  2. Filik L., Oğuz D., (Treatment of Hepatocellular Carcinoma), Güncel Gastroenteroloji 2003; 7(1): 74-79
  3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-524
  4. Llovet JM, Bustamente J, Castells A. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-67
  5. Sturk C, Dumont D. In: Tannock IF, Hill RP, Bristow RG, et al, eds. Basic Science of Oncology. 4th ed. New York, NY: Mc- Graw-Hill; 2005:231-248
  6. Edmondson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48900 necropsies. Cancer 1954; 7:462-503
  7. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980; 64: 1263-1272
  8. Davila JA, Morgan RO, Shaib Y, Shaib Y McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a populationbased study. Gastroenterology 2004; 127: 1372-1380
  9. Arii S, Yamaoka Y, Futagawa S, Inoue K Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000; 32:1224-1229
  10. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145-151
  11. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699
  12. Karakayali H, Sevmis S, Moray G, Yilmaz U, Ozcay F, Savas NA, Arslan G, Haberal M. Liver transplantation in patients with hepatocellular carcinoma: one center's experience. Transplant Proc 2008; 40:213- 218
  13. Kiyici M, Yilmaz M, Akyildiz M, Arikan C, Aydin U, Sigirli D, Nart D, Yilmaz F Ozacar T, Karasu Z, Kilic M. Association between hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation. Transplant Proc 2008;40:1511-1517
  14. Haberal M, Emiroglu R, Karakayali H Moray G, Yilmaz U, Ozçay F, Bilezikci B Arslan G. Expanded criteria for hepatocellular carcinoma and